Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis

Enrico Maria Zardi, Antonio Picardi, Giovanni Ambrosino, Vito Michele Fazio, Aldo Dobrina, Mauro Frego, Antonella Afeltra, Franco Lumachi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Iloprost, a prostacyclin analog, reduces hepatic microcirculatory damage after ischemia-reperfusion injury in animal liver models. The objective of this study was to evaluate whether the portal flow velocity changes after Iloprost infusion in patients with systemic sclerosis and Raynaud's phenomenon, who usually have increased risk of microvascular thrombosis and transient liver disturbances. Patients and Methods: Fifteen patients (3 males and 12 females, median age 58 years, range 47-66 years), with systemic sclerosis and Raynaud's phenomenon, were exclusively treated with an infusion of Iloprost (2 ng/ kg/min, 6 h/day) for 5 days. In each subject, the portal flow velocity (PV, cm/sec) and portal flow volume (PFV, mL/min) were obtained by using portal color Doppler ultrasonography equipment. Results: Iloprost admin istration significantly (p

Original languageEnglish
Pages (from-to)377-380
Number of pages4
JournalIn Vivo
Volume20
Issue number3
Publication statusPublished - May 2006

Fingerprint

Iloprost
Systemic Scleroderma
Flow velocity
Raynaud Disease
Liver
Doppler Color Ultrasonography
Ultrasonography
Epoprostenol
Reperfusion Injury
Animals
Thrombosis
Animal Models
Color
Equipment and Supplies

Keywords

  • Color Doppler ultrasonography
  • Hepatic microcircle
  • Iloprost
  • Portal flow
  • Raynaud's phenomenon
  • Systemic sclerosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zardi, E. M., Picardi, A., Ambrosino, G., Fazio, V. M., Dobrina, A., Frego, M., ... Lumachi, F. (2006). Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis. In Vivo, 20(3), 377-380.

Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis. / Zardi, Enrico Maria; Picardi, Antonio; Ambrosino, Giovanni; Fazio, Vito Michele; Dobrina, Aldo; Frego, Mauro; Afeltra, Antonella; Lumachi, Franco.

In: In Vivo, Vol. 20, No. 3, 05.2006, p. 377-380.

Research output: Contribution to journalArticle

Zardi, EM, Picardi, A, Ambrosino, G, Fazio, VM, Dobrina, A, Frego, M, Afeltra, A & Lumachi, F 2006, 'Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis', In Vivo, vol. 20, no. 3, pp. 377-380.
Zardi EM, Picardi A, Ambrosino G, Fazio VM, Dobrina A, Frego M et al. Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis. In Vivo. 2006 May;20(3):377-380.
Zardi, Enrico Maria ; Picardi, Antonio ; Ambrosino, Giovanni ; Fazio, Vito Michele ; Dobrina, Aldo ; Frego, Mauro ; Afeltra, Antonella ; Lumachi, Franco. / Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis. In: In Vivo. 2006 ; Vol. 20, No. 3. pp. 377-380.
@article{4e09ede870c54da88fed60b56dcbcb2e,
title = "Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis",
abstract = "Background: Iloprost, a prostacyclin analog, reduces hepatic microcirculatory damage after ischemia-reperfusion injury in animal liver models. The objective of this study was to evaluate whether the portal flow velocity changes after Iloprost infusion in patients with systemic sclerosis and Raynaud's phenomenon, who usually have increased risk of microvascular thrombosis and transient liver disturbances. Patients and Methods: Fifteen patients (3 males and 12 females, median age 58 years, range 47-66 years), with systemic sclerosis and Raynaud's phenomenon, were exclusively treated with an infusion of Iloprost (2 ng/ kg/min, 6 h/day) for 5 days. In each subject, the portal flow velocity (PV, cm/sec) and portal flow volume (PFV, mL/min) were obtained by using portal color Doppler ultrasonography equipment. Results: Iloprost admin istration significantly (p",
keywords = "Color Doppler ultrasonography, Hepatic microcircle, Iloprost, Portal flow, Raynaud's phenomenon, Systemic sclerosis",
author = "Zardi, {Enrico Maria} and Antonio Picardi and Giovanni Ambrosino and Fazio, {Vito Michele} and Aldo Dobrina and Mauro Frego and Antonella Afeltra and Franco Lumachi",
year = "2006",
month = "5",
language = "English",
volume = "20",
pages = "377--380",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis

AU - Zardi, Enrico Maria

AU - Picardi, Antonio

AU - Ambrosino, Giovanni

AU - Fazio, Vito Michele

AU - Dobrina, Aldo

AU - Frego, Mauro

AU - Afeltra, Antonella

AU - Lumachi, Franco

PY - 2006/5

Y1 - 2006/5

N2 - Background: Iloprost, a prostacyclin analog, reduces hepatic microcirculatory damage after ischemia-reperfusion injury in animal liver models. The objective of this study was to evaluate whether the portal flow velocity changes after Iloprost infusion in patients with systemic sclerosis and Raynaud's phenomenon, who usually have increased risk of microvascular thrombosis and transient liver disturbances. Patients and Methods: Fifteen patients (3 males and 12 females, median age 58 years, range 47-66 years), with systemic sclerosis and Raynaud's phenomenon, were exclusively treated with an infusion of Iloprost (2 ng/ kg/min, 6 h/day) for 5 days. In each subject, the portal flow velocity (PV, cm/sec) and portal flow volume (PFV, mL/min) were obtained by using portal color Doppler ultrasonography equipment. Results: Iloprost admin istration significantly (p

AB - Background: Iloprost, a prostacyclin analog, reduces hepatic microcirculatory damage after ischemia-reperfusion injury in animal liver models. The objective of this study was to evaluate whether the portal flow velocity changes after Iloprost infusion in patients with systemic sclerosis and Raynaud's phenomenon, who usually have increased risk of microvascular thrombosis and transient liver disturbances. Patients and Methods: Fifteen patients (3 males and 12 females, median age 58 years, range 47-66 years), with systemic sclerosis and Raynaud's phenomenon, were exclusively treated with an infusion of Iloprost (2 ng/ kg/min, 6 h/day) for 5 days. In each subject, the portal flow velocity (PV, cm/sec) and portal flow volume (PFV, mL/min) were obtained by using portal color Doppler ultrasonography equipment. Results: Iloprost admin istration significantly (p

KW - Color Doppler ultrasonography

KW - Hepatic microcircle

KW - Iloprost

KW - Portal flow

KW - Raynaud's phenomenon

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=33646823258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646823258&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 377

EP - 380

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 3

ER -